NASDAQ:JYNT Joint (JYNT) Stock Price, News & Analysis $12.45 +0.44 (+3.66%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Joint Stock (NASDAQ:JYNT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Joint alerts:Sign Up Key Stats Today's Range$11.70▼$12.5450-Day Range$9.70▼$12.5152-Week Range$9.58▼$15.32Volume122,863 shsAverage Volume54,273 shsMarket Capitalization$190.52 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingBuy Company OverviewThe Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.Read More… Joint Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreJYNT MarketRank™: Joint scored higher than 58% of companies evaluated by MarketBeat, and ranked 290th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingJoint has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJoint has only been the subject of 1 research reports in the past 90 days.Read more about Joint's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth381.82% Earnings GrowthEarnings for Joint are expected to grow by 381.82% in the coming year, from $0.11 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Joint is -10.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Joint is -10.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJoint has a P/B Ratio of 7.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Joint's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.77% of the float of Joint has been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Joint has recently decreased by 0.03%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJoint does not currently pay a dividend.Dividend GrowthJoint does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.77% of the float of Joint has been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Joint has recently decreased by 0.03%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment0.92 News SentimentJoint has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Joint this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Joint insiders have not sold or bought any company stock.Percentage Held by Insiders27.90% of the stock of Joint is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.88% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Joint's insider trading history. Receive JYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter. Email Address JYNT Stock News HeadlinesThe Joint Corp. Names Business Transformation and Growth Expert Scott J. Bowman Chief Financial OfficerJune 10 at 6:53 PM | uk.finance.yahoo.comThe Joint Corp. Names Business Transformation and Growth Expert Scott J. Bowman Chief Financial OfficerJune 10 at 4:20 PM | globenewswire.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.June 12, 2025 | Brownstone Research (Ad)Joint (NASDAQ:JYNT) to Repurchase $5.00 million in Outstanding Stock June 7, 2025 | americanbankingnews.comThe Joint Corp stock surges on repurchase planJune 5, 2025 | in.investing.comJoint Corp. board authorizes $5M share repurchase, commencing August 2025June 5, 2025 | msn.comJoint Corp. Appoints New Director and ChairJune 5, 2025 | tipranks.comThe Joint Corp. Announces $5 Million Stock Repurchase ProgramJune 5, 2025 | globenewswire.comSee More Headlines JYNT Stock Analysis - Frequently Asked Questions How have JYNT shares performed this year? Joint's stock was trading at $10.63 at the start of the year. Since then, JYNT stock has increased by 17.1% and is now trading at $12.45. View the best growth stocks for 2025 here. How were Joint's earnings last quarter? The Joint Corp. (NASDAQ:JYNT) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.01. The firm had revenue of $13.08 million for the quarter, compared to analysts' expectations of $13.02 million. Joint had a positive trailing twelve-month return on equity of 8.24% and a negative net margin of 13.95%. Read the conference call transcript. Is Joint buying back stock? Joint's Board of Directors authorized a stock buyback program on Thursday, June 5th 2025, which authorizes the company to buy back $5,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 2.7% of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its stock is undervalued. When did Joint IPO? Joint (JYNT) raised $20 million in an initial public offering on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager. Who are Joint's major shareholders? Top institutional shareholders of Joint include Skylands Capital LLC (4.91%), Alta Fox Capital Management LLC (2.63%), Topline Capital Management LLC (2.47%) and Goldman Sachs Group Inc. (2.22%). View institutional ownership trends. How do I buy shares of Joint? Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Joint own? Based on aggregate information from My MarketBeat watchlists, some other companies that Joint investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/08/2025Today6/12/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Patent owners & lessors Sub-IndustryTrading Current SymbolNASDAQ:JYNT CIK1612630 Webwww.thejoint.com Phone(480) 245-5960Fax480-513-7989Employees320Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$16.00 Low Stock Price Target$15.00 Potential Upside/Downside+30.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E Ratio108.18 P/E GrowthN/ANet Income-$9.75 million Net Margins-13.95% Pretax Margin-4.59% Return on Equity8.24% Return on Assets2.33% Debt Debt-to-Equity RatioN/A Current Ratio1.44 Quick Ratio1.44 Sales & Book Value Annual Sales$52.79 million Price / Sales3.45 Cash Flow$0.76 per share Price / Cash Flow15.65 Book Value$1.68 per share Price / Book7.08Miscellaneous Outstanding Shares15,303,000Free Float10,459,000Market Cap$182.11 million OptionableOptionable Beta1.48 Social Links 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:JYNT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersElon’s final win for Social Security?Elon's Successor? Elon Musk and President Trump's new feud is all over the news... but before he left Washi...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Joint Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Joint With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.